One of the primary US certified environmental testing services, Holista Colltech Limited (ASX:HCT) has completed testing its Path-Away® against the virus SARS-CoV-2 that triggers Covid-19. The research was carried out by Microbac Laboratories, Inc.
Path-Away® attained a 3-Log reduction, about 99.9% of the virus within the span of two minutes, on a hard surface. Log reduction stands for a 10-fold or 90% reduction in numbers of live bacteria. Therefore, a 3-Log reduction suggests 99.9% decline in the likely harmful microorganisms.
Meanwhile, Path-Away® as an anti-pathogenic aerosol solution, was successfully tested on the substitute of SARS-CoV-2 in April 2020.
According to the GICC-LLC, Global Infection Control Consultants, this is expected to be the world’s first completely natural and organic disinfectant, meeting the USA assessment guidelines.
Path-Away® is the active component in sanitizers NatShield™ and Protectene™, both formulated by Holista.
HCT share price quoted at $0.130 at AEDT 01:50 PM on 20 October 2020.
_08_05_2022_17_51_18_349554.png "What happened to the Elon Musk and Twitter Deal?")
_08_05_2022_17_47_36_436510.png "Which ASX Stocks are the easiest to buy?")
_08_05_2022_17_41_37_958727.png "What does China Own in Australia?")
Be the First to Comment